Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes
Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes
复制标题
DOI：
10.1161/circinterventions.117.005359
复制
发表时间：
2017-11-01
影响因子：
5.6
通讯作者：
Rodes-Cabau, Josep
中科院分区：
文献类型：
--
作者：
Asmarats, Lluis;Rodes-Cabau, Josep
慢性口服抗凝治疗是预防房颤患者血栓栓塞事件的标准治疗方法。然而，口服抗凝与出血事件的风险增加有关，尽管引入直接口服抗凝剂有所改善，但仍有超过三分之一的房颤患者未接受治疗。在过去的十年中，经皮左心耳封闭术已成为预防房颤患者中风/全身栓塞的有效替代抗凝治疗方法。在本文中，我们提供了当前经导管左心耳关闭装置的最新概述，并回顾了与左心耳关闭相关的结果，重点是程序和晚期结果，并指出了未来的方向。
Chronic oral anticoagulation therapy is the standard therapy for preventing thromboembolic events in patients with atrial fibrillation. However, oral anticoagulation has been associated with an increased risk of bleeding events, and despite the improvements linked to the introduction of direct oral anticoagulants, more than one third of atrial fibrillation patients still remain untreated. Over the past decade, percutaneous left atrial appendage closure has emerged as a valid alternative to anticoagulation therapy for the prevention of stroke/systemic embolism in patients with atrial fibrillation. In this article, we provide an updated overview of current transcatheter left atrial appendage closure devices and review the results associated with left atrial appendage closure, focusing on procedural and late outcomes, and pointing to future directions.